Ashley Pastorius

Clinical Research Nurse eager to contribute advancement of nursing sciences through hard work, attention to detail, and excellent organizational skills. Well-versed in study protocols, standard operating procedures, and general trial oversight. Ready to bring related experience to a challenging new role.

• Good Clinical Practice
• IATA Dangerous Goods Certificate
• Critical Care Registered Nurse
• Conscious Sedation Certification
• Advanced Cardiovascular Life Support
• Pediatric Advanced Life Support
• Basic Life Support

• Neurocritical Care Association/ Conference
• American Association of Critical Care Nurses
• Cleveland Clinic Nursing Research Symposium
• FAU/Cleveland Clinic Neurosciences Research Symposium
• Cleveland Clinic Engagement Committee
• Best Preceptor of the Year at Saint Josephs Hospital
• Outstanding Preceptor from Saint Petersburg Community College
• Daisy Award for Compassionate Care

Stroke- Primary Study Coordinator, RN 

• NIH Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) Phase 2a trial
• NIH Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)
• NIH Anticoagulation in Intracerebal Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

Neurosurgery- Primary Study Coordinator, RN

• A Randomized, Single-Blinded, Non-Inferiority Study Comparing AGN1 Local Osteo Enhancement Procedure (LOEP) SV Kit Treatment of Vertebral Compression Fragility Fractures to PMMA Bone Cement Treatment
• Kaneka Endovascular Embolization and Protection (KEEP) Post Market Study
• ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized Evaluation (RESTORE)
• Prospective SpineJack System Registry

Neurology- Primary Study Coordinator, RN

• A Two-Part Study of REC-994 in the Treatment of Adults with Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy, and Pharmcokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994 (RECURSION)
• A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus (RAISE)

Cardiology- Primary Study Coordinator, RN 

• A Multi-Site Observational Clinical Investigation to Collect Non-invasive Sensor Data During a Right Heart Catheterization and Train Machine Learning Models to Estimate Intracardiac Hemodynmaic Parameters (ACORAI)
• The Rhythm Evaluation for AntiCoagulation with Continuous Monitoring of Atrial Fibrillation (REACT-AF)

Oncology- Back Up Study Coordinator, RN 

• A multicentre, Phase II, Single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or boarderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC) (MDT Bridge)
• A Randomized, Open-label, Phase 3 Study of Adjuvant Sactiuzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-Gilead)
• A Phase III, Double-Blind, Placebo-Controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)
• A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II-IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Infectious Disease- Back Up Study Coordinator, RN 

• A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)